FIT Biotech Overview
- Founded
- 1995

- Status
- Private
- Employees
- 11

- Latest Deal Type
- IPO
- Latest Deal Amount
- $20.2M

FIT Biotech General Information
Description
FIT Biotech Oy is a clinical-stage biotechnology company. It is primarily focused on developing antibody therapies for cancer immunotherapy as well as Deoxyribonucleic acid (DNA) vaccines for the prevention of infectious diseases such as Human immunodeficiency virus (HIV). The firm's GTU technology enables the production of antibodies in the human body instead of using industrially manufactured antibodies. The GTU technology platform has various application areas. The group generates revenue through the sales of services related to the HIV vaccine. The organization is based in Finland.
Contact Information
- Biokatu 8
- 33520 Tampere
- Finland
FIT Biotech Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. IPO | 01-Jul-2015 | $20.2M | 000.00 | 000.00 | Completed | Generating Revenue |
1. Early Stage VC | 29-Jun-2006 | 00.000 | 00.000 | Completed | Product Development |
FIT Biotech Patents
FIT Biotech Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20110171255-A1 | Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant | Granted | 23-May-2008 | 000000000 | 0 |
US-9474800-B2 | Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant | Active | 23-May-2008 | 000000000 | 0 |
AU-2009248735-A1 | Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant | Granted | 23-May-2008 | 000000000 | |
CA-2724570-A1 | Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant | Abandoned | 23-May-2008 | 000000000 | |
AU-2009248735-B2 | Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant | Ceased | 23-May-2008 | A61K39/39 |
FIT Biotech Executive Team (3)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Erkki Pekkarinen | Chief Executive Officer | ||
James Kuo MD | Chief Executive Officer |
FIT Biotech Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialFIT Biotech Acquisitions (1)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
00000000 | 23-Jan-2003 | 0000000000 | Other Devices and Supplies | 000000 00 |